159 related articles for article (PubMed ID: 37256703)
21. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
[TBL] [Abstract][Full Text] [Related]
22. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy.
Go J; Ahn JH; Park JM; Choi SB; Kim JY; Park HS; Kim SI; Park BW; Park S
Ann Surg Oncol; 2023 Nov; 30(12):7060-7068. PubMed ID: 37537485
[TBL] [Abstract][Full Text] [Related]
23. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
24. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.
Zarotti C; Papassotiropoulos B; Elfgen C; Dedes K; Vorburger D; Pestalozzi B; Trojan A; Varga Z
Sci Rep; 2022 Jan; 12(1):91. PubMed ID: 34997055
[TBL] [Abstract][Full Text] [Related]
25. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
Xu X; Zhao W; Liu C; Gao Y; Chen D; Wu M; Li C; Wang X; Song X; Yu J; Liu Z; Yu Z
BMC Cancer; 2024 Jan; 24(1):13. PubMed ID: 38166846
[TBL] [Abstract][Full Text] [Related]
26. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
27. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
[TBL] [Abstract][Full Text] [Related]
28. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
29. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
[No Abstract] [Full Text] [Related]
30. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
31. Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study.
Kim Y; Sim SH; Park B; Chae IH; Han JH; Jung SY; Lee S; Kwon Y; Park IH; Ko K; Lee CW; Lee KS; Kang HS; Lee ES
Sci Rep; 2021 Jan; 11(1):634. PubMed ID: 33436702
[TBL] [Abstract][Full Text] [Related]
32. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
33. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Bossuyt V; Provenzano E; Symmans WF; Boughey JC; Coles C; Curigliano G; Dixon JM; Esserman LJ; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Viale G; Cameron D;
Ann Oncol; 2015 Jul; 26(7):1280-91. PubMed ID: 26019189
[TBL] [Abstract][Full Text] [Related]
34. The Prognostic Value of the AJCC 8th Edition Staging System for Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
Kantor O; Bao J; Jaskowiak N; Yao K; Tseng J
Ann Surg Oncol; 2020 Feb; 27(2):352-358. PubMed ID: 31376037
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
Provenzano E
Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
[TBL] [Abstract][Full Text] [Related]
37. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
38. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer.
Prakash I; Neely NB; Thomas SM; Sammons S; Blitzblau RC; DiLalla GA; Hyslop T; Menendez CS; Plichta JK; Rosenberger LH; Fayanju OM; Hwang ES; Greenup RA
Cancer Med; 2022 Feb; 11(4):1099-1108. PubMed ID: 34989142
[TBL] [Abstract][Full Text] [Related]
39. [Correlation between HER2 expression before neoadjuvant treatment and RCB classification after surgical treatment in breast cancer].
Ma YQ; Wang XR; Liu YP
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1169-1173. PubMed ID: 33152824
[No Abstract] [Full Text] [Related]
40. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]